FDA advisors recommend AstraZeneca, Sanofi antibody to protect babies from RSV

[ad_1]

If the Food and Drug Administration approves nirsevimab, it will be the first medical intervention available in the U.S. that can protect infants from RSV.

[ad_2]

Source link